secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001636282-23-000016
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea BioTherapeutics Q3 2023 net loss $40.1M; cash $204.9M; IBD pipeline on track
--------------------------------------------------------------------------------

- Net loss $40.1M in Q3 2023 vs $18.2M a year ago, reflecting $24.7M R&D (+106% YoY) and $21.8M other expense.
- Cash, equivalents, marketable securities and restricted cash $204.9M at Sept 30, 2023, expected runway into 2026.
- SPY001 anti-α4β7 IND expected H1 2024; healthy volunteer interim data year-end 2024.
- SPY002 anti-TL1A IND expected H2 2024; picomolar affinity for monomer/trimer cited.
- Stockholder vote Nov 21 to authorize preferred-to-common conversion; sold pegzilarginase to Immedica for $15M upfront plus milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628223000016/0001636282-23-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628223000016/agle-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001636282-23-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer